Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
The dystrophin pre-mRNA exon 51 splicing enhancer is a regulatory sequence within the DMD gene transcript that promotes the inclusion of exon 51 during pre-mRNA splicing (FDA, 2016). In Duchenne muscular dystrophy (DMD) patients with specific deletions, the inclusion of exon 51 results in an out-of-frame mRNA transcript, leading to a complete lack of functional dystrophin protein (NIH, 2023). This target is specifically utilized by antisense oligonucleotides (ASOs) to induce exon skipping. By binding to this enhancer sequence, drugs like eteplirsen sterically block the spliceosome's access, causing exon 51 to be omitted from the final mRNA (PubChem, 2024). This intervention restores the reading frame, enabling the synthesis of a truncated but internally functional dystrophin protein, which can mitigate the severe muscle wasting characteristic of the disease (Nature Reviews Drug Discovery, 2011). The resulting protein is similar to the partially functional dystrophin found in patients with the milder Becker muscular dystrophy. This therapeutic approach represents a significant advancement in precision medicine for genetic neuromuscular disorders.
Antisense oligonucleotide binding to the exonic splicing enhancer to sterically block the splicing machinery, resulting in the exclusion of exon 51 from the mature mRNA transcript (FDA, 2016).
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Dystrophin pre-mRNA exon 51 splicing enhancer (DMD exon 51 ESE) (DMD exon 51 ESE).